Epidemiological EMESIS-Registry

iOMEDICO AG1,035 enrolled

Overview

The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.

Study Type

OBSERVATIONAL

Enrollment

1,035

Conditions

Antiemetic Therapy

Interventions

non-interventionalOTHER

non-interventional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid. * start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given \>= 24 months ago. * Compliance with registry procedures * Age \>= 18 years * WHO Performance Status of 0 or 1 (Karnofsky-Index \>= 70%) * Life expectancy of at least 12 weeks * Signed and dated informed consent before the start of the registry Exclusion Criteria: * Mentally incapable or incompliant patients * Last chemotherapy \<= 24 months (if pretreated) * Known hypersensitivity to antiemetic medication * unability of the patient to be treated with oral medication * pregnancy or lactation period

Locations (1)

iOMEDICO AG

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Outcomes

Primary Outcomes

Efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.

Time frame: 4 chemotherapy applications per patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.